Cold Chain Qualification: 5 Questions You Must Ask When Shipping Biologics

| January 20, 2017

article image
"Cold Chain" refers to the undisrupted series of logistical activities of products that must be maintained within a given temperature range. Maintaining cold chain is critical to the integrity of biologically derived therapeutic products. Patient safety and regulatory compliance are the key drivers within cold chain logistical systems. Organizations recognize the growing need for control of the entire cold chain. The ever changing global scenario requires highly efficient processes as a backbone to accommodate the growing needs of organizations.

Spotlight

BRDG Park

The Bio Research & Development Growth (BRDG) Park at the Danforth Plant Science Center offers leading bio-research facilities with world-class wet labs, office space for lease and on-site workforce training. Emerging scientific enterprises get just the right combination for success – interactions between top scientists and access to state-of-the-art core facilities such as technologically advanced greenhouses, growth chambers, microscopy, proteomics and tissue transformation facilities, as well as other vital resources.

OTHER ARTICLES

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

5 Biotech Stocks Winning the Coronavirus Race

Article | April 13, 2020

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Spotlight

BRDG Park

The Bio Research & Development Growth (BRDG) Park at the Danforth Plant Science Center offers leading bio-research facilities with world-class wet labs, office space for lease and on-site workforce training. Emerging scientific enterprises get just the right combination for success – interactions between top scientists and access to state-of-the-art core facilities such as technologically advanced greenhouses, growth chambers, microscopy, proteomics and tissue transformation facilities, as well as other vital resources.

Events